Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)

Newsfile March 1, 2023

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

GlobeNewswire February 28, 2023

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

GlobeNewswire February 21, 2023

Algernon Pharma (CSE:AGN) safe to proceed to next phase of DMT clinical study

Jonathon Brown February 16, 2023

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

GlobeNewswire February 16, 2023

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

TheNewsWire January 17, 2023

Algernon Pharmaceuticals  (CSE:AGN) subsidiary doses first subject in Phase 1 DMT clinical stroke study

Brieanna McCutcheon  January 17, 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

GlobeNewswire January 17, 2023

Algernon Pharmaceuticals (CSE:AGN) appoints Dr. Peter Dicpinigaitis to its Chronic Cough Advisory Board

John Ballem  January 11, 2023

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

GlobeNewswire January 11, 2023

Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

TheNewsWire January 10, 2023

Algernon Pharmaceuticals (CSE:AGN) announces upcoming phase 2b chronic cough study of Ifenprodil

John Ballem  January 9, 2023

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

GlobeNewswire January 9, 2023

Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

TheNewsWire January 4, 2023

Algernon Pharmaceuticals (CSE:AGN) announces private subsidiary and SEC filing

Trevor Abes  January 3, 2023

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

GlobeNewswire January 3, 2023

Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

John Ballem  December 5, 2022

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire December 5, 2022

Algernon Pharmaceuticals (CSE:AGN) screens first subject in Phase 1 DMT Human Stroke Study

Jonathon Brown November 16, 2022

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

GlobeNewswire November 16, 2022